Venus Medtech (Hangzhou) Inc
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company's offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to tre… Read more
Venus Medtech (Hangzhou) Inc (VMTHF) - Total Assets
Latest total assets as of June 2025: $3.12 Billion USD
Based on the latest financial reports, Venus Medtech (Hangzhou) Inc (VMTHF) holds total assets worth $3.12 Billion USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Venus Medtech (Hangzhou) Inc - Total Assets Trend (2017–2024)
This chart illustrates how Venus Medtech (Hangzhou) Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Venus Medtech (Hangzhou) Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Venus Medtech (Hangzhou) Inc's total assets of $3.12 Billion consist of 24.7% current assets and 75.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.2% |
| Accounts Receivable | $331.12 Million | 10.2% |
| Inventory | $98.06 Million | 3.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $443.45 Million | 13.7% |
| Goodwill | $1.04 Billion | 32.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Venus Medtech (Hangzhou) Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Venus Medtech (Hangzhou) Inc's current assets represent 24.7% of total assets in 2024, a decrease from 62.7% in 2017.
- Cash Position: Cash and equivalents constituted 9.2% of total assets in 2024, down from 30.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 44.0% of total assets, an increase from 12.0% in 2017.
- Asset Diversification: The largest asset category is goodwill at 32.0% of total assets.
Venus Medtech (Hangzhou) Inc Competitors by Total Assets
Key competitors of Venus Medtech (Hangzhou) Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cheelcare Inc.
V:CHER
|
Canada | CA$4.27 Million |
|
FluroTech Ltd
OTCQB:FLURF
|
USA | $282.20K |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩119.28 Billion |
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
Venus Medtech (Hangzhou) Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Venus Medtech (Hangzhou) Inc generates 0.14x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Venus Medtech (Hangzhou) Inc is currently not profitable relative to its asset base.
Venus Medtech (Hangzhou) Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.82 | 2.22 | 14.99 |
| Quick Ratio | 1.56 | 1.97 | 14.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $329.30 Million | $ 600.79 Million | $ 2.92 Billion |
Venus Medtech (Hangzhou) Inc - Advanced Valuation Insights
This section examines the relationship between Venus Medtech (Hangzhou) Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.62 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -26.4% |
| Total Assets | $3.25 Billion |
| Market Capitalization | $114.03 Million USD |
Valuation Analysis
Below Book Valuation: The market values Venus Medtech (Hangzhou) Inc's assets below their book value (0.04 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Venus Medtech (Hangzhou) Inc's assets decreased by 26.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Venus Medtech (Hangzhou) Inc (2017–2024)
The table below shows the annual total assets of Venus Medtech (Hangzhou) Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.25 Billion | -26.37% |
| 2023-12-31 | $4.41 Billion | -16.45% |
| 2022-12-31 | $5.28 Billion | +3.39% |
| 2021-12-31 | $5.11 Billion | +18.32% |
| 2020-12-31 | $4.32 Billion | +17.70% |
| 2019-12-31 | $3.67 Billion | +254.69% |
| 2018-12-31 | $1.03 Billion | +433.16% |
| 2017-12-31 | $194.01 Million | -- |